Insights Into the Role of Cannabinoids in the Management of Endometriosis-Associated Pain [ID 3776]

INTRODUCTION: Endometriosis is a chronic inflammatory gynecological disorder characterized by the presence of endometrial-like tissue outside the uterus, leading to debilitating chronic pain. Despite its significant effect on women’s quality of life, there remains an unmet clinical need for effective pain management strategies for endometriosis-associated pain. In recent years, the endocannabinoid system has emerged as a potential therapeutic target for endometriosis-related pain, owing to its anti-inflammatory, antinociceptive, and analgesic properties. This review aims to provide an overview of the potential mechanisms of action by which cannabinoids may modulate endometriosis, and discuss possible therapeutic applications for endometriosis-associated pain. METHODS: An extensive literature review was conducted using the online database PubMed up to March 2025, with keywords including “endometriosis,” “chronic pelvic pain,” “endocannabinoid system,” “cannabinoids,” and “cannabis.” We included observational studies in humans, as well as experiments in vitro or in animal models. RESULTS: Preclinical evidence suggests that cannabinoids modulate endometriosis-associated pain by reducing inflammatory mediator release, inhibiting nociceptive signaling by acting on cannabinoid, TRPV1, and PPAR-γ receptors in endometriotic lesions, and modulating neuroinflammation and central sensitization. Cannabinoids also exert antiproliferative and proapoptotic effects on endometriotic lesions, potentially limiting disease progression. CONCLUSIONS/IMPLICATIONS: While preclinical studies demonstrate the potential of cannabinoids as a novel therapeutic option for endometriosis-associated pain, there is a lack of large-scale, rigorous human clinical trials to support their use. Clinical trials investigating the long-term safety and efficacy of cannabinoids, particularly among women of reproductive age, are urgently needed to establish the effectiveness of cannabis in endometriosis.

Authors

Institutions

Publication Details

Journal
Obstetrics and Gynecology
Published
2026-04-30
DOI
https://doi.org/10.1097/aog.0000000000006265.28
Primary Topic
Cannabis and Cannabinoid Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Insights Into the Role of Cannabinoids in the Management of Endometriosis-Associated Pain [ID 3776]

Husam M. Abu‐Soud, Olivia G. Camp, Vanessa L. Veltre, Mia M. Biernat et al.
Obstetrics and Gynecology
Cannabis and Cannabinoid Research
article

Insights Into the Role of Cannabinoids in the Management of Endometriosis-Associated Pain [ID 3776]

Husam M. Abu‐Soud, Olivia G. Camp, Vanessa L. Veltre, Mia M. Biernat, Alexandra M. Stone
article en

Abstract

INTRODUCTION: Endometriosis is a chronic inflammatory gynecological disorder characterized by the presence of endometrial-like tissue outside the uterus, leading to debilitating chronic pain. Despite its significant effect on women’s quality of life, there remains an unmet clinical need for effective pain management strategies for endometriosis-associated pain. In recent years, the endocannabinoid system has emerged as a potential therapeutic target for endometriosis-related pain, owing to its anti-inflammatory, antinociceptive, and analgesic properties. This review aims to provide an overview of the potential mechanisms of action by which cannabinoids may modulate endometriosis, and discuss possible therapeutic applications for endometriosis-associated pain. METHODS: An extensive literature review was conducted using the online database PubMed up to March 2025, with keywords including “endometriosis,” “chronic pelvic pain,” “endocannabinoid system,” “cannabinoids,” and “cannabis.” We included observational studies in humans, as well as experiments in vitro or in animal models. RESULTS: Preclinical evidence suggests that cannabinoids modulate endometriosis-associated pain by reducing inflammatory mediator release, inhibiting nociceptive signaling by acting on cannabinoid, TRPV1, and PPAR-γ receptors in endometriotic lesions, and modulating neuroinflammation and central sensitization. Cannabinoids also exert antiproliferative and proapoptotic effects on endometriotic lesions, potentially limiting disease progression. CONCLUSIONS/IMPLICATIONS: While preclinical studies demonstrate the potential of cannabinoids as a novel therapeutic option for endometriosis-associated pain, there is a lack of large-scale, rigorous human clinical trials to support their use. Clinical trials investigating the long-term safety and efficacy of cannabinoids, particularly among women of reproductive age, are urgently needed to establish the effectiveness of cannabis in endometriosis.

Obstetrics and GynecologyVol. 147(5S)
Wayne State University (US)
Good health and well-being
Openalex Percentile: Top 8%
Cannabis and Cannabinoid Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.